NEW YORK, Feb. 27, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Inotek Pharmaceuticals Corporation (“Inotek”) (NASDAQ:ITEK) between July 23, 2015 and December 30, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra/inotek-pharmaceuticals-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.
On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of of $1.75 per share on January 3, 2017.
If you suffered a loss in Inotek you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions
Meta Partners With Reliance to Launch First AI-Powered Data Center in India
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion
Woodside Energy Acquires PetroChina’s Browse Stake, Expands Position in Major Australian Gas Project
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion
Frasers Group Launches €2 Billion Hugo Boss Takeover Offer Amid Control Speculation
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 



